Pharvaris (NASDAQ:PHVS) Forecasted to Earn Q4 2024 Earnings of ($0.54) Per Share

Pharvaris (NASDAQ:PHVS) – Equities researchers at Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for Pharvaris in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.54) per share for the quarter, up from their previous forecast of ($0.55). The consensus estimate for Pharvaris’ current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Pharvaris’ FY2025 earnings at ($2.15) EPS.

PHVS has been the topic of a number of other reports. JMP Securities upped their target price on shares of Pharvaris from $49.00 to $50.00 and gave the stock a “market outperform” rating in a research note on Thursday, April 11th. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Pharvaris in a report on Thursday, April 11th. Finally, Morgan Stanley lowered their target price on Pharvaris from $35.00 to $34.00 and set an “overweight” rating for the company in a report on Monday.

Pharvaris Stock Down 13.1 %

PHVS opened at $18.42 on Thursday. Pharvaris has a one year low of $7.93 and a one year high of $33.00. The stock’s 50 day moving average price is $24.20 and its 200-day moving average price is $23.26.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors have recently bought and sold shares of PHVS. Tower Research Capital LLC TRC purchased a new stake in shares of Pharvaris in the 3rd quarter valued at $26,000. UBS Group AG purchased a new stake in Pharvaris in the fourth quarter valued at $32,000. Qube Research & Technologies Ltd purchased a new stake in Pharvaris in the third quarter valued at $54,000. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% during the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock worth $105,000 after purchasing an additional 5,272 shares during the period. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Pharvaris during the 4th quarter valued at about $183,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).